The need for sacral nerve stimulation is further fueled by the growing elderly population. People are more likely to experience incontinence and other disorders requiring sacral nerve stimulation as they age. Additionally, aging can weaken the pelvic floor and bladder muscles, increasing the risk of urine incontinence. Technological developments in sacral nerve stimulation are also driving the market's growth. New gadgets like wireless networking, greater battery life, and better programming add modern features. These developments result in improvements in patient outcomes and a rise in market adoption.
A further factor anticipated to drive the market is a surge in patient and healthcare provider knowledge of sacral nerve stimulation. As more patients learn about these devices' advantages, medical professionals advise patients to use them as a therapy option for urinary incontinence issues. This market is expanding due to the availability of advantageous reimbursement schemes. Sacral nerve stimulation is becoming more widely covered by insurance companies and governments, which makes it more accessible to patients. As a result, the market is expanding, and there is an increase in the usage of these gadgets.
The NHS spends over £6.5 billion every year on obesity, the second-leading cancer preventive cause, according to the government's most recent data in June 2023. In England, there are more than one in four adults who are obese (26%) and 23.4% of children who are 10 to 11 years old. This puts a tremendous strain on the health and care systems. Stress incontinence arises as a result of this. The bladder becomes hyperactive as a result of this. In the approaching years, there may be a demand for sacral nerve stimulation in the region due to the region's rising obesity rate and the increased likelihood that overweight and obese people would get UI.
The Germany market dominated the Europe Sacral Nerve Stimulation Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $38.5 Million by 2030. The UK market is estimated to witness a CAGR of 4% during (2023-2030). Additionally, The France market would showcase a CAGR of 5.7% during (2023-2030).
Based on Application, the market is segmented into Urinary & Fecal Incontinence, Chronic Anal Fissure, and Others. Based on Product, the market is segmented into Devices, and Accessories. Based on End-user, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, Axonics, Inc., Beijing PINS Medical Co., Ltd., PZMed, Laborie Medical Technologies, Synapse BioMedical, Inc., Johnson and Johnson, LivaNova PLC, Boston Scientific Corporation, and Saluda Medical Pty Ltd.
Scope of the Study
By Application
- Urinary & Fecal Incontinence
- Chronic Anal Fissure
- Others
By Product
- Devices
- Accessories
By End-user
- Hospitals
- Specialty Clinics
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Medtronic PLC
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- PZMed
- Laborie Medical Technologies
- Synapse BioMedical, Inc.
- Johnson and Johnson
- LivaNova PLC
- Boston Scientific Corporation
- Saluda Medical Pty Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Medtronic PLC
- Axonics, Inc.
- Beijing PINS Medical Co., Ltd.
- PZMed
- Laborie Medical Technologies
- Synapse BioMedical, Inc.
- Johnson and Johnson
- LivaNova PLC
- Boston Scientific Corporation
- Saluda Medical Pty Ltd.
Methodology
LOADING...